Ferrologix, Inc. SBIR Phase I Award,

Immunoassays which minimize sample usage are a critical need to develop personalized therapeutics like immunotherapy and precision immunomodulatory devicesThis often involves the isolation and analysis of specific cell types from blood or tissue samplesUnfortunatelythe current workflows needed to isolate these cell populations utilize magnetic cell sorting and or flow cytometry which are expensivedifficult to scale and not sample sparringFerrologix has developed a novelsample sparring cell purification platform based on a technology called ratcheting cytometryThe ratcheting cytometry platform has demonstrated high purity enrichmentrtof target cells from minimal sample volumesL or ltmillion cellseven with rare cell populationsltThe technology has been developed to a translational pointTRLand is being beta tested by potential customers at several remote sitesIn this phase I effortFerrologix seeks accelerate commercial translation of its platform towards an immediate customerGE Global Researchin testing a new immunomodulation ultrasonic device for treating inflammatory responsesFerrologix will deploy one of its prototype instruments with accompanying cartridges to GE who will use the platform to isolate and analyze cytokine activity of human PBMCs and rodent macrophages as part on an ongoing preclinical study